Atossa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2010
Net Income	-30.09	-26.96	-20.61	-22.33	-17.24	Upgrade
Depreciation & Amortization	0.02	0.01	0.02	0.05	0.05	Upgrade
Share-Based Compensation	4.62	6.79	5.27	3.02	8.84	Upgrade
Other Operating Activities	4.51	-0.6	-1.16	3.19	-0.79	Upgrade
Operating Cash Flow	-20.94	-20.76	-16.47	-11.57	-9.13	Upgrade
Capital Expenditures	-0.01	-0.03	-0.01	-0.01	-0.01	Upgrade
Change in Investments	0	-4.7	0	0	0	Upgrade
Investing Cash Flow	-0.01	-4.73	-0.01	-0.01	-0.01	Upgrade
Share Issuance / Repurchase	-1.48	0	113.88	33.62	11.34	Upgrade
Other Financing Activities	-	-	-0.57	4.93	-	Upgrade
Financing Cash Flow	-1.48	0	113.3	38.55	11.34	Upgrade
Net Cash Flow	-22.43	-25.49	96.82	26.97	2.2	Upgrade
Free Cash Flow	-20.96	-20.79	-16.48	-11.58	-9.14	Upgrade
Free Cash Flow Per Share	-0.17	-0.16	-0.14	-1.02	-1.07	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).